As the 70-year-old CEO of EDP Biotech Corp. in Knoxville, Tom Boyd (at left, in shirt from another venture) must be an interesting guy, and his firm probably deserves the sudden buzz they're getting, as a result of their announcement Friday, which read in part, saying the company has introduced a "revolutionary new technology for a simple blood test to detect early-stage colon cancer. Following the success of its pre-clinical trials for the ColoMarker™ assay, EDP has filed a patent on the biomarker, CA11-19, and all aspects of its use. Via an inexpensive blood test, ColoMarker™ will detect colon cancer in its earliest, most curable stages."
Showing posts with label diagnostics. Show all posts
Showing posts with label diagnostics. Show all posts
Sunday, December 20, 2009
Cancer-detection breakthrough
As the 70-year-old CEO of EDP Biotech Corp. in Knoxville, Tom Boyd (at left, in shirt from another venture) must be an interesting guy, and his firm probably deserves the sudden buzz they're getting, as a result of their announcement Friday, which read in part, saying the company has introduced a "revolutionary new technology for a simple blood test to detect early-stage colon cancer. Following the success of its pre-clinical trials for the ColoMarker™ assay, EDP has filed a patent on the biomarker, CA11-19, and all aspects of its use. Via an inexpensive blood test, ColoMarker™ will detect colon cancer in its earliest, most curable stages."
Thursday, December 17, 2009
NeoGenomics appointment
NeoGenomics Inc. (NASD OTC BB: NGNM), the Fort Myers, Fla.-based company that has a cancer genetics diagnostic lab in Nashville's Grassmere Park, announced it's named Jack Spitz vice president over lab operations. Spitz was previously in charge of operations for Orlando, Fla.-based Dermpath Diagnostics, a division of Quest Diagnostics.
Subscribe to:
Posts (Atom)
